Skip to main content
Caplight Logo









Diamond Therapeutics

Diamond Therapeutics

Private
TorontoHealthcare & Life Scienceshttps://www.diamondthera.com/

Last Round

Grant

May 11, 2026

Total Funding Raised

$8.55M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Diamond Therapeutics is a biotechnology company that develops sub-perceptual, non-hallucinogenic psychedelic-based medicines for the treatment of mental health conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

psychedelic medicinepsilocybin therapynon-hallucinogenicneuroplastogensmental health treatmentbiotechnologydrug discoverysub-perceptualclinical trialstryptamine analogsmicrodosingpsychedelic biotechtake-at-home therapyneuropsychiatric disorderssmall molecule drugs

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Diamond Therapeutics Comparables

Compare Diamond Therapeutics with similar companies based on industry and business-model similarity.

Diamond Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Transneural Therapeutics, Inc.
86%
Delix Therapeutics
85%
Xylo Bio
83%

Diamond Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 11, 2026
SeedApr 4, 2023
Convertible DebtJan 7, 2021
SeedApr 1, 2020

Key People

Founding team and executive leadership

Judy Blumstock

Founder & CEO

Founding Team

Grant McCutcheon

Chief Financial Officer

Executive Team

Diamond Therapeutics Investors

Notable investors and investment history

Diamond Therapeutics investors
InvestorRounds
Ontario Brain InstituteConvertible Debt
ARPA-HGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 255% MoM, reaching 703.

  • May 11, 2026

    $4M grant from ARPA-H

Diamond Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Diamond Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Diamond Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersToronto
Employee Range7
Year Founded2018
Last FundingMay 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?